Compare PEO & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEO | IMMX |
|---|---|---|
| Founded | 1929 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 673.6M | 736.1M |
| IPO Year | N/A | 2021 |
| Metric | PEO | IMMX |
|---|---|---|
| Price | $25.15 | $12.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $19.20 |
| AVG Volume (30 Days) | 74.0K | ★ 2.0M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 5.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.57 | $1.94 |
| 52 Week High | $28.88 | $11.61 |
| Indicator | PEO | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 51.44 | 71.99 |
| Support Level | $20.94 | $7.99 |
| Resistance Level | $27.13 | N/A |
| Average True Range (ATR) | 0.49 | 0.90 |
| MACD | 0.06 | 0.23 |
| Stochastic Oscillator | 74.07 | 93.59 |
Adams Natural Resources Fund Inc is a non-diversified U.S. equity fund that invests in liquid energy and other natural resources stocks. The Fund's investment objectives are preservation of capital, reasonable income, and opportunity for capital gain. A majority of its assets are invested in the petroleum or natural resources industries or industries connected to them. It has broad flexibility to invest in stocks of varying capitalizations and predominantly invests in stocks found in the S&P 500 Energy and S&P 500 Materials sectors.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.